AccuLine’s CORA system employs an advanced signal filtering method combined with deep learning algorithms to evaluate the condition of a patient’s coronary arteries. The Israeli startup AccuLine has recently completed a $4.2 million Seed round, led by eHealth Ventures and Maccabi Healthcare Services. This round includes grants from the Israel Innovation Authority and Google’s AI Startups Fund. Additionally, the company secured capital from Mayo Clinic, a leading U.S. medical center, with which it has signed a know-how agreement to develop CORA for the U.S. market. The funding will support the continued development and commercialization of the CORA system, aimed at early detection of coronary artery disease (CAD).
AccuLine, founded in early 2022, was established by CEO Moshe Barel, Prof. Aharon Frimerman (head of the Interventional Cardiology unit at Hillel Yaffe Medical Center), Prof. Shai Revzen (a computer science professor at the University of Michigan), and Benny Shani (the company’s CTO). The company operates with a team of seven in Petah Tikva and has raised a total of $5.5 million to date.
AccuLine’s solution addresses a critical unmet need in the medical field. Heart attacks remain the leading cause of death globally, yet front-line diagnostic tools for early CAD detection are limited. Current popular stress ECG tests lack accuracy, and invasive procedures like cardiac CT or coronary angiography require contrast media injection, expose patients to radiation, and are costly with long waiting times. These invasive exams are typically not covered by insurance unless patients show symptoms or are at high risk.
The CORA system by AccuLine offers a quick, easy, and non-invasive test that can be performed in a family doctor’s office by any medical staff member. In just a few minutes, CORA simultaneously analyzes three biological signals: the heart’s electrical function, oxygen saturation, and breathing phase. Through advanced signal filtering and deep learning algorithms, CORA assesses the condition of the patient’s coronary arteries to guide appropriate treatment.
